title: Quantification of blood dendritic cells in colorectal cancer patients during the course of disease.
abstract: Colorectal cancer is a malignancy with poor prognosis that might be associated with defective immune function. The aim of the present study was to investigate circulating dendritic cells in colorectal cancer patients, in order to contribute to elucidate tumor-escape mechanisms and to point out a possible correlation with the clinical condition of the disease. Therefore, we enumerated ex vivo myeloid and plasmacytoid dendritic cells, through multicolor flow cytometry, in 26 colorectal patients and 33 healthy controls. Furthermore we performed several analyses at determined time points in order to define the immunological trend of cancer patients after surgery and other conventional treatments. At the pre-operative time point the absolute number of plasmacytoid dendritic cells in cancer patients was significantly reduced in comparison to controls, this result being mainly referred to stage III-IV patients. The number of myeloid dendritic cells did not show any significant difference compared to healthy controls; interestingly the expression of the tolerogenic antigen CD85k was significantly higher on cancer patients' myeloid dendritic cells than controls'. At the following samplings, circulating dendritic cell absolute number did not show any difference compared to controls. Conclusively the impairment of the number of circulating dendritic cells may represent one of the tumor escape mechanisms occurring in colorectal cancer. These alterations seem to be correlated to cancer progression. Our work sheds light on one of dendritic cell-based tumor immune escape mechanisms. This knowledge may be useful to the development of more effective immunotherapeutic strategies.
authors.affiliation: Department of Experimental and Clinical Medicine, University of Pisa, via Roma 67, Pisa, 56126, Italy, giulia.orsini@for.unipi.it.
authors.forename: Giulia
authors.initials: G
authors.lastname: Orsini
authors.forename: Annalisa
authors.initials: A
authors.lastname: Legitimo
authors.forename: Alessandra
authors.initials: A
authors.lastname: Failli
authors.forename: Paola
authors.initials: P
authors.lastname: Ferrari
authors.forename: Andrea
authors.initials: A
authors.lastname: Nicolini
authors.forename: Roberto
authors.initials: R
authors.lastname: Spisni
authors.forename: Paolo
authors.initials: P
authors.lastname: Miccoli
authors.forename: Rita
authors.initials: R
authors.lastname: Consolini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism; D016022:Case-Control Studies; D002452:Cell Count / Q000379:methods; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D003713:Dendritic Cells / Q000378:metabolism*; D005260:Female; D006801:Humans; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D008297:Male; D008875:Middle Aged; D022423:Myeloid Cells / Q000378:metabolism*; D011971:Receptors, Immunologic / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C105299:LILRB1 protein, human; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D011971:Receptors, Immunologic
references.citation: Br J Cancer. 2003 Oct 20;89(8):1463-72
references.pmid: 14562018
references.citation: Biochim Biophys Acta. 2009 Jan;1795(1):16-24
references.pmid: 18675885
references.citation: Crit Rev Oncol Hematol. 2008 Mar;65(3):191-9
references.pmid: 18055210
references.citation: Breast Cancer Res. 2006;8(1):101
references.pmid: 16469120
references.citation: World J Gastroenterol. 2007 Nov 28;13(44):5822-31
references.pmid: 17990348
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Int Immunol. 2012 Jun;24(6):347-56
references.pmid: 22345276
references.citation: Int J Colorectal Dis. 2012 Feb;27(2):159-69
references.pmid: 22065108
references.citation: J Exp Med. 1997 May 19;185(10):1743-51
references.pmid: 9151699
references.citation: Radiother Oncol. 2012 Jul;104(1):131-8
references.pmid: 22682747
references.citation: Clin Immunol. 2005 Jan;114(1):52-60
references.pmid: 15596409
references.citation: Immunol Cell Biol. 2005 Oct;83(5):451-61
references.pmid: 16174093
references.citation: J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4
references.pmid: 11501971
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):265-77
references.pmid: 22437871
references.citation: Cancer Treat Rev. 2012 Aug;38(5):451-66
references.pmid: 21945823
references.citation: Ann Surg Oncol. 2007 Oct;14(10):2854-60
references.pmid: 17593331
references.citation: Clin Cancer Res. 2005 Apr 1;11(7):2576-82
references.pmid: 15814636
references.citation: Clin Cancer Res. 2002 Jun;8(6):1787-93
references.pmid: 12060618
references.citation: J Surg Res. 2012 Apr;173(2):299-308
references.pmid: 21195425
references.citation: Semin Immunopathol. 2011 Jul;33(4):335-40
references.pmid: 21461991
references.citation: Cell Immunol. 2010;263(2):138-47
references.pmid: 20434139
references.citation: Exp Dermatol. 2009 Mar;18(3):264-73
references.pmid: 19183400
references.citation: J Immunol. 2007 Feb 1;178(3):1534-41
references.pmid: 17237402
references.citation: Cancer. 1989 Feb 1;63(3):496-503
references.pmid: 2912528
references.citation: Cancer Immunol Immunother. 2004 Nov;53(11):978-86
references.pmid: 15197496
references.citation: Prostate. 2007 Jan 1;67(1):1-7
references.pmid: 17075798
references.citation: Hum Immunol. 2009 May;70(5):340-4
references.pmid: 19275918
references.citation: PLoS One. 2011;6(11):e27944
references.pmid: 22125641
references.citation: World J Gastroenterol. 2006 May 28;12(20):3275-82
references.pmid: 16718852
references.citation: Clin Exp Immunol. 2003 Nov;134(2):270-8
references.pmid: 14616787
references.citation: Clin Cancer Res. 2004 Nov 1;10(21):7260-9
references.pmid: 15534100
references.citation: Immunol Invest. 2006;35(3-4):459-83
references.pmid: 16916762
references.citation: Anticancer Res. 2005 Sep-Oct;25(5):3541-6
references.pmid: 16101177
references.citation: Cancer Res. 2007 Mar 1;67(5):1883-6
references.pmid: 17332313
references.citation: Curr Opin Immunol. 2010 Apr;22(2):206-11
references.pmid: 20144853
references.citation: Clin Immunol. 2006 Oct;121(1):74-80
references.pmid: 16914380
references.citation: Blood. 2005 Nov 15;106(10):3490-7
references.pmid: 16030186
references.citation: Blood. 2002 Jul 1;100(1):230-7
references.pmid: 12070032
references.citation: APMIS. 2008 Jun;116(6):445-56
references.pmid: 18754318
references.citation: Cancer Res. 2003 Oct 1;63(19):6478-87
references.pmid: 14559840
references.citation: Anticancer Res. 2003 Nov-Dec;23(6a):4423-6
references.pmid: 14666729
references.citation: Cancer Immunol Immunother. 2006 Jul;55(7):775-84
references.pmid: 16167144
references.citation: J Transl Med. 2007 Nov 29;5:62
references.pmid: 18047662
references.citation: Prostate. 2006 Feb 1;66(2):180-92
references.pmid: 16173035
references.citation: Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57
references.pmid: 12672517
references.citation: Scand J Immunol. 2010 Dec;72(6):540-7
references.pmid: 21044128
references.citation: Trends Immunol. 2010 Jan;31(1):18-23
references.pmid: 19836307
references.citation: Cell Immunol. 2007 Jul;248(1):59-67
references.pmid: 17923119
references.citation: Cancer Immunol Immunother. 2006 Feb;55(2):151-9
references.pmid: 15889251
references.citation: Exp Gerontol. 2007 Oct;42(10):1033-8
references.pmid: 17606348
references.citation: Curr Opin Immunol. 2010 Apr;22(2):258-63
references.pmid: 20226644
references.citation: Gene. 2004 Apr 28;331:159-64
references.pmid: 15094202